Table 5.

Multivariate Logistic Regression Analysis for Occurrences of PSA Flare during Chemotherapy in Patients with CRPC

PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; CI, confidence interval; PSADT1, PSA doubling time calculated using the conventional interval from the first rise greater than the nadir during androgen deprivation therapy until the start of the next treatment; PSADT2, PSA doubling time calculated using the period from the initial rise after anti-androgen withdrawal until the start of chemotherapy; ratio of PSA doubling time, PSADT2/PSADT1.